A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22-Reference-Cited by-同舟云学术

A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

Published:2015-10-21 Issue:1 Volume:4 Page:
ISSN:2193-1801
Container-title:SpringerPlus
language:en
Short-container-title:SpringerPlus

Author:

Trudeau Maureen Elizabeth,Chapman Judith-Anne W.,Guo Baoqing,Clemons Mark J.,Dent Rebecca A.,Jong Roberta A.,Kahn Harriette J.,Pritchard Kathleen I.,Han Lei,O’Brien Patti,Shepherd Lois E.,Parissenti Amadeo M.

Funder

Canadian Cancer Society Research Institute (CA)

Ontario Institute for Cancer Research (CA)

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://link.springer.com/content/pdf/10.1186/s40064-015-1392-x.pdf

Reference50 articles.

1. Aigner J, Schneeweiss A, Sohn C, Marme F (2011) The role of neoadjuvant chemotherapy in the management of primary breast cancer. Minerva Ginecol 63(3):261–274

2. Ammann JU, Cooke A, Trowsdale J (2013) Butyrophilin Btn2a2 inhibits TCR activation and phosphatidylinositol 3-kinase/Akt pathway signaling and induces Foxp3 expression in T lymphocytes. J Immunol 190(10):5030–5036

3. Araki T, Milbrandt J (2000) Ninjurin2, a novel homophilic adhesion molecule, is expressed in mature sensory and enteric neurons and promotes neurite outgrowth. J Neurosci 20(1):187–195

4. Benusiglio PR, Pharoah PD, Smith PL, Lesueur F, Conroy D, Luben RN, Dew G, Jordan C, Dunning A, Easton DF, Ponder BA (2006) HapMap-based study of the 17q21 ERBB2 amplicon in susceptibility to breast cancer. Br J Cancer 95(12):1689–1695

5. Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang C, Jinsui W, Min Z (2012) Upregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res 31:70

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel Strategies Using Sagacious Targeting for Site-Specific Drug Delivery in Breast Cancer Treatment: Clinical Potential and Applications;Critical Reviews™ in Therapeutic Drug Carrier Systems;2024

2. Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer;JNCI Cancer Spectrum;2023-12-19

3. Association of extensive RNA disruption with natural killer cell-mediated death of K562 chronic myelogenous leukemia cells;2023-06-05

4. Behavioral, Electrophysiological, and Histological Characterization of a New Rat Model for Neoadjuvant Chemotherapy–Induced Neuropathic Pain: Therapeutic Potential of Duloxetine and Allopregnanolone Concomitant Treatment;Neurotoxicity Research;2020-02-27

5. Drug Combinations in Breast Cancer Therapy;Pharmaceutical Nanotechnology;2019-05-10